In: Herz Kardiovaskuläre Erkrankungen, 2005, vol. 30, no. 3, p. 189-196
|
In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 296-300
|
|
In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 301-306
|
In: European Heart Journal, 2013, vol. 34, no. 18, p. 1375-1383
|
In: European Heart Journal, 2011, vol. 32, no. 24, p. 3115-3127
|
In: European Heart Journal, 2011, vol. 32, no. 22, p. 2748-2757
|
In: European Journal of Cardio-Thoracic Surgery, 2015, vol. 47, no. 5, p. 860-861
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: Archives of Cardiovascular Diseases, 2012, vol. 105, no. 11, p. 587–592
Objectifs Le but de cette étude est de comparer l’effet sur l’agrégation plaquettaire de la molécule originale de clopidogrel (clopidogrel bisulfate [Plavix®]) aux molécules génériques (clopidogrel besylate [clopidogrel Sandoz®] et clopidogrel hydrochloride [clopidogrel-Mepha®]) et au prasugrel (Efient®). Historique On suspecte que le sel utilisé pour lier la molécule de...
|